Get the Stockscreener App
13.52
4.16%
0.54
Greenwich Lifesciences Inc stock is traded at $13.52, with a volume of 40,531.
It is up +4.16% in the last 24 hours and down -31.72% over the past month.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.
See More
Previous Close:
$12.98
Open:
$13.54
24h Volume:
40,531
Relative Volume:
0.26
Market Cap:
$199.04M
Revenue:
-
Net Income/Loss:
$-21.76M
P/E Ratio:
-8.7344
EPS:
-1.5479
Net Cash Flow:
$-12.78M
1W Performance:
-3.91%
1M Performance:
-31.72%
6M Performance:
-59.72%
1Y Performance:
+16.85%
1-Day Range:
$13.36
$14.08
1-Week Range:
$12.51
$15.36
52-Week Range:
$7.78
$34.10
Greenwich Lifesciences Inc Stock (GLSI) Company Profile
Name
Greenwich Lifesciences Inc
Sector
Industry
Phone
203-434-3290
Address
3992 BLUEBONNET DR, BUILDING 14, STAFFORD
Compare GLSI vs VRTX, REGN, ARGX, RVMD, ALNY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLSI
Greenwich Lifesciences Inc
|
13.56 | 190.52M | 0 | -21.76M | -12.78M | -1.5479 |
VRTX
Vertex Pharmaceuticals Inc
|
485.40 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
674.35 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
907.15 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
189.37 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
283.43 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Greenwich Lifesciences Inc Stock (GLSI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | Noble Capital Markets | Outperform |
| Sep-01-21 | Initiated | H.C. Wainwright | Buy |
Greenwich Lifesciences Inc Stock (GLSI) Latest News
Form 4 Greenwich Lifesciences Inc For: 27 July By Investing.com - Investing.com Canada
Greenwich LifeSciences CEO buys $47,018 in company stock By Investing.com - Investing.com Canada
Greenwich LifeSciences (NASDAQ: GLSI) CEO adds 3,600 shares in open-market buys - Stock Titan
Greenwich LifeSciences, Inc. Revenue Breakdown – NASDAQ:GLSI - TradingView
TradingKey - TradingKey
Greenwich Lifesciences Inc (GLSI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Greenwich Lifesciences Inc (GLSI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
GLSI|Greenwich Lifesciences Inc|Price:12.980|Chg%:-0.210 - TradingKey
Greenwich Lifesciences Inc (GLSI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Greenwich Lifesciences Inc (GLSI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Greenwich Lifesciences Inc (GLSI) Institutional Confidence - TradingKey
Greenwich LifeSciences, Inc. (GLSI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Greenwich LifeSciences, Inc. (GLSI) stock price, news, quote and history - Yahoo Finance UK
Why Did GLSI Stock Rise Pre-Market Today? - Stocktwits
Greenwich LifeSciences adds up to 10 UK trial sites - grafa.com
Greenwich LifeSciences gains UK approval for breast cancer trial By Investing.com - Investing.com South Africa
Greenwich LifeSciences Gets UK Clearance to Expand Breast Cancer Trial - Moomoo
Greenwich LifeSciences gains UK approval for breast cancer trial - Investing.com
Greenwich LifeSciences secures regulatory approval to expand FLAMINGO-01 trial into United Kingdom - Traders Union
Greenwich LifeSciences Announces UK Regulatory Approval to Expand Phase III FLAMINGO-01 Breast Cancer Trial - Quiver Quantitative
Greenwich LifeSciences Announces Approval to Expand FLAMINGO-01 into the United Kingdom - The Manila Times
UK approval could add 5-10 sites to Greenwich LifeSciences trial - Stock Titan
Greenwich LifeSciences: Building Pivotal Trial Momentum, But Still Not Moving The Needle For Me - Seeking Alpha
Greenwich LifeSciences expands Phase III breast cancer trial - grafa.com
Why is Greenwich LifeSciences stock rallying today? By Investing.com - Investing.com Canada
Greenwich LifeSciences updates phase III breast cancer trial design By Investing.com - Investing.com South Africa
Greenwich LifeSciences updates phase III breast cancer trial design - Investing.com
Greenwich LifeSciences Updates FLAMINGO-01 Phase III Trial Design, Enrollment and Financial Outlook - Quiver Quantitative
Greenwich trial opens enrollment to patients representing about 55% of population - Stock Titan
The Technical Signals Behind (GLSI) That Institutions Follow - Stock Traders Daily
Greenwich LifeSciences wins EMA clearance to combine HLA patient groups in FLAMINGO-01 trial - Bitget
Greenwich LifeSciences expands trial enrollment in Europe By Investing.com - Investing.com South Africa
Greenwich unifies 180-site FLAMINGO-01 trial protocol - grafa.com
Greenwich LifeSciences Announces European Approval For Combining Both HLA Populations In FLAMINGO-01 - marketscreener.com
Greenwich LifeSciences expands trial enrollment in Europe - Investing.com
Greenwich LifeSciences Announces European Approval for Combining Both HLA Populations in FLAMINGO-01 - GlobeNewswire
Greenwich LifeSciences' breast cancer drug shows strong Phase 2 results but faces funding risks ahead of Phase 3. - Pluang
Greenwich LifeSciences The Overlooked Need (NASDAQ:GLSI) - Seeking Alpha
Greenwich Lifesciences Receives European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 - marketscreener.com
Greenwich LifeSciences (GLSI) Rallies 3.6% as Biotech Stock Approaches Key ResistanceFade Trade - DonanımHaber
Greenwich LifeSciences stock jumps as EMA approves commercial GP2 By Investing.com - Investing.com Canada
Greenwich LifeSciences stock jumps as EMA approves commercial GP2 - Investing.com
Greenwich LifeSciences Secures EMA Approval for Phase 3 GP2 Lot - grafa.com
Sector Update: Healthcare - Moomoo
Sector Update: Healthcare Stocks Mixed Pre-Bell Thursday - Moomoo
Greenwich LifeSciences Says Commercially Manufactured GP2 Cleared for Trial in Europe - Moomoo
European regulators authorize Greenwich LifeSciences to deploy commercial GP2 in FLAMINGO-01 study - Traders Union
Greenwich LifeSciences Announces EMA Approval for Commercially Manufactured GP2 in FLAMINGO-01 Across Europe - Quiver Quantitative
Greenwich LifeSciences Announces European Approval for Use of Commercially Manufactured GP2 in FLAMINGO-01 - GlobeNewswire
Europe joins U.S. in using commercial GP2 for Greenwich’s breast cancer trial - Stock Titan
Greenwich Lifesciences Inc announced that its commercial production of Gp2 has been approved for use in the Flamingo-01 study in Europe. - Bitget
Greenwich Lifesciences Inc Stock (GLSI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.58%
1.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):